Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
RUT
Market Cap
248.21M
Enterprise Value
239.33M
Income
-21.68M
Sales
0.00M
Book/sh
0.21
Cash/sh
0.60
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13
IPO
Sep 25, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
79.63
P/C
27.95
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.54
Current Ratio
1.54
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-1.52
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
-33.14% -57.71%
Sales past 3/5Y
- -
EPS Y/Y TTM
-11.31%
Sales Y/Y TTM
-
EPS Q/Q
10.27%
Sales Q/Q
-
Insider Own
47.91%
Insider Trans
0.10%
Inst Own
11.68%
Inst Trans
-0.85%
ROA
-361.30%
ROE
-951.64%
ROIC
-695.56%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
4.05%
SMA50
2.15%
SMA200
-20.59%
Trades
Shs Outstand
14.68M
Shs Float
7.65M
52W High
34.10 -50.41%
52W Low
7.78 117.35%
Volatility
9.81% 9.14%
ATR (14)
1.45
RSI (14)
51.95
Beta
1.57
Rel Volume
0.76
Avg Volume
129.38K
Volume
56,328
Perf Week
2.73%
Perf Month
2.30%
Perf Quarter
8.75%
Perf Half Y
-29.92%
Perf YTD
-19.51%
Perf Year
95.27%
Perf 3Y
68.76%
Perf 5Y
-54.56%
Perf 10Y
-
Prev Close
15.17
Price
16.91
Change %
11.47%
Consensus
Strong Buy
Avg. Price Target
$57.00
Implied Upside
+237.1%
Analysts2incl. previous ratings
Rating Distribution2 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 20, 2025Initiated
NNoble Capital Markets
Outperform$45+166.1%
Sep 01, 2021Initiated
HH.C. Wainwright
Buy$78+361.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel SnehalCEO and CFOJul 28 '26Buy13.591,50020,3855,610,702Jul 30 06:05 AM
Patel SnehalCEO and CFOJul 29 '26Buy13.107009,1705,611,402Jul 30 06:05 AM
Patel SnehalCEO and CFOJul 27 '26Buy13.621,50020,4305,609,202Jul 29 06:05 AM
Patel SnehalCEO and CFOJul 23 '26Buy13.142,50032,8505,606,602Jul 27 06:15 AM
Patel SnehalCEO and CFOJul 24 '26Buy12.881,10014,1685,607,702Jul 27 06:15 AM
Patel SnehalCEO and CFOJan 13 '26Buy29.831,80053,6945,604,102Jan 15 06:05 AM
Patel SnehalCEO and CFOJan 12 '26Buy27.542,90079,8665,602,302Jan 14 06:05 AM
Patel SnehalCEO and CFODec 31 '25Buy21.364,30091,8485,599,402Jan 05 06:06 AM
Patel SnehalCEO and CFODec 30 '25Buy21.732,90063,0175,595,102Jan 02 06:05 AM
Patel SnehalCEO and CFODec 18 '25Buy12.624,10051,7425,592,202Dec 19 06:05 AM
Patel SnehalCEO and CFONov 25 '25Buy8.374,60038,5025,588,102Nov 28 06:05 AM
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
CEOMr. Snehal S. Patel
Founder & Independent DirectorMr. Eric Rothe
Chief Medical Officer & DirectorDr. Frank Joseph Daugherty M.D.
Vice President Clinical & Regulatory AffairsDr. Jaye L. Thompson Ph.D.
VP of Business DevelopmentDr. Christine T. Fischette Ph.D.